Galena
Biopharma is a developer of targeted oncology treatments designed to address
major unmet medical needs to advance cancer care. The company is making
significant progress in the advancement of candidates in its portfolio, guided
by a management team comprised of experienced biotech management and scientists
with a vision to accelerate value for both patients and shareholders.
Mark
J. Ahn, Ph.D., backed with more than 20 years of experience in the
biopharmaceutical industry, has served as Galena’s president and CEO since
March 31, 2011, and as a director since 2007. He is also an adjunct professor
of biosciences at Creighton University. Dr. Ahn previously was a principal at
Pukana Partners, Ltd., which provides strategic consulting to life science companies;
and associate professor of global management at Atkinson Graduate School of
Management, Willamette University. Among other achievements, Dr. Ahn was also
founder and CEO of Hana Biosciences; vice president of hematology and corporate
officer at Genentech, Inc.; and held positions of increasing responsibility at
Amgen and Bristol-Myers Squibb. Aside from serving on several boards of
directors, Dr. Ahn has authored more than 50 peer reviewed journal articles and
books. He is educated with a B.A. and M.B.A. from Chaminade University; an M.A.
from Victoria University; was a graduate fellow in Economics at Essex
University; and obtained a Ph.D. from the University of South Australia.
Galena’s
executive vice president and Chief Medical Officer Dr. Brian Hamilton, M.D.,
Ph.D has extensive academic and pharmaceutical experience in immunology,
hematopoietic stem cell transplantation, and oncology. Through his tenure with
pharmaceutical and biotech companies, Dr. Hamilton’s experience includes drug
development across multiple therapeutic indications and platforms, including
small molecules, biologics, oncolytic viruses, and vaccines. Dr. Hamilton
received his M.D. and Ph.D. from the University of Washington School of
Medicine with extensive specialty training to include pediatrics at the
Children’s Medical Center in Dallas, Texas; immunology at the Children’s
Hospital Medical Center and Sidney Farber Cancer Center; and allergy at the
University of California-San Francisco. He has held academic appointments at the
University of Washington and the University of Miami.
Prior
to his current role as Galena’s executive vice president and chief operating
officer, Dr. Mark W. Schwartz served as executive vice president and COO of RXi
Pharmaceuticals; president and CEO of Bayhill Therapeutics, a company
developing a DNA vaccine platform for the treatment of autoimmune diseases
where he completed a successful partnership with Genentech for the development
of the company’s type 1 diabetes vaccine; and president and CEO of Calyx
Therapeutics, which doubled its size and completed key phase I and phase II
international clinical trials of novel anti-inflammatory compounds during his
tenure.
The
doctors are supported by a management team of highly qualified individuals as
well as scientific and advisory boards.
For
more information, visit www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
